Monday’s rapid fire: Chevron, Snap, Intel, Abbvie and Colgate

All right. So let’s move into the rapid fire. Now while we start with Chevron, you had an earnings beat despite a missile in revenues. You know, maybe this is a chance to buy some oil, frankly, because I’ve been itching to buy. Devon, this was incredible. I mean, I thought it was a great quarter. Dingo high, Snap Ink, much better than expected quarter, high revenues. Active users made a profit. The consumer product goods companies like it because they’ve got the younger people to reach it. So it’s very positive. And then we talked about Intel a little bit. Yeah, an earnings beat, but guidance very weak. Found your business. The guidance was shockingly weak and it made me think, is the balance sheet good enough Abby? The stock initially was higher off, a better than expected quarter, but Botox misses. They did raise their full year outlook and some longer term sales projection on a few key drugs, maybe concerns about Humira. With the with generics, right, biosimilars, biosimilars and then Colgate strong quarter organic sales up 9.8 raises a full year sales guidance to 5.7%. So I I they did better than Procter, I admit that on the Procter. But you know the Matt Horween tell me ’cause he’s always looking at one of my partner, reverse head and shoulders that. That’s a very powerful thing. I think that’s this thought goes to 100. They have a tremendous charts there about how much better things are going and people realize kind of crazy.